We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Effectiveness of Bupropion Combined With Behavioral Therapy for Treating Methamphetamine Dependence - 2

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: August 26, 2005
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
University of California, Los Angeles
Information provided by:
National Institute on Drug Abuse (NIDA)
Methamphetamine is an addictive stimulant drug that strongly activates certain parts of the brain. The purpose of this study is to determine the effectiveness of bupropion in combination with behavioral therapy for the treatment of methamphetamine addiction.

Condition Intervention Phase
Methamphetamine Drug: Bupropion Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Evaluation of Bupropion vs Placebo for the Treatment of Methamphetamine Dependence

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Addiction severity, Week 16
  • Drug use, Week 16

Enrollment: 73
Study Start Date: October 2005
Study Completion Date: May 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Drug: Bupropion
Placebo Comparator: 2
Drug: Placebo

Detailed Description:

Methamphetamine is a drug that causes excess amounts of the neurotransmitters dopamine and norepinephrine to be released into the brain. This overload produces unusual alertness and feelings of elation. When the body undergoes methamphetamine withdrawal, it experiences a reduction in dopamine and norepinephrine. Bupropion is an antidepressant used for the treatment of depression and smoking cessation. Because it functions by increasing the release of dopamine and norepinephrine in the brain, bupropion is likely to decrease the negative effects of methamphetamine withdrawal. The purpose of this study is to evaluate the efficacy of bupropion combined with contingency management (CM) and cognitive behavioral counseling (CBT) as a means of treating methamphetamine dependence.

An initial 2-week screening process will involve participants providing urine samples and completing physical and psychological assessments. If deemed eligible for the remainder of this double-blind study, participants will be randomly assigned to receive either bupropion or placebo over the course of 12 weeks. Participants in both the bupropion and placebo groups will receive contingency management and cognitive behavioral counseling. Participants will report to one of two clinical research sites three times per week. At each visit, participants will be examined by the study staff, provide a urine sample, and receive individual cognitive behavioral counseling sessions. At the end of 12 weeks, treatment will be stopped. Participants will return to the study site 30 days later for evaluation and to be assessed for any possible lingering side effects.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Meets DSM-IV criteria for methamphetamine dependence
  • Females must use an effective method of contraception

Exclusion Criteria:

  • History of or current medical condition that might interfere with safe participation, such as active tuberculosis, unstable heart or liver disease, unstable diabetes, symptomatic AIDS (non-symptomatic HIV infection is not an exclusion), or greater than 8 times the upper limit of normal in liver screening function tests (SGOT or SGPT)
  • Current neurological disorder (e.g., organic brain disease, dementia)
  • Major psychiatric disorder unrelated to substance abuse, such as schizophrenia or bipolar disorder (assessed by the SCID and a medical history)
  • Suicide attempt within the month prior to enrollment and/or currently suicidal (assessed by the SCID and the BDI II)
  • Currently on prescription medication that might interact with the study drug
  • Currently dependent on cocaine, opiates, alcohol, or benzodiazepines, as defined by DSM-IV-TR criteria
  • History of alcohol dependence within past three years
  • History of seizure disorders
  • History of anorexia or bulimia
  • Current hypertension uncontrolled by medication
  • History of sensitivity to bupropion
  • Pregnant or breastfeeding
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00135785

United States, California
UCLA Medical Center
Los Angeles, California, United States, 90024
Rancho Cucamonga Clinic
Rancho Cucamonga, California, United States, 91730
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
University of California, Los Angeles
Principal Investigator: Steve Shoptaw, Ph.D. University of California, Los Angeles
  More Information

Responsible Party: Dr Steven Shoptaw, UCLA Department of Family Medicine
ClinicalTrials.gov Identifier: NCT00135785     History of Changes
Other Study ID Numbers: NIDA-18185-2
First Submitted: August 23, 2005
First Posted: August 26, 2005
Last Update Posted: January 12, 2017
Last Verified: September 2009

Additional relevant MeSH terms:
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Central Nervous System Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic Agents
Adrenergic Uptake Inhibitors